Co-Author E. Carragee summarized four (4) separate FDA regulated, randomized, non-blinded investigational device trials of rhBMP-2 and OP-1 use compared to ICBG for spinal fusion. The study cited:
"...no significant increase in back pain scores or functional disability at any time after surgery for those subjects undergoing the ICBG harvesting..."
"...(ICBG) did not appear to affect post-operative pain, function, or occupational activities in the best comparative trials we have."
(E. Carragee, "Pseudomorbidity in iliac crest bone harvesting: the rise of rhBMP-2 in short segment posterior lumbar fusion" The Spine Journal 9 (2009) 873-879)